VNRX•prnewswire•
Volition Continues to Extend Access to Nu.Q® Vet Cancer Test
Summary
HENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 20, 2026 by prnewswire